TECVAYLI plus DARZALEX FASPRO modelling suggests longer survival in early line relapsed multiple myeloma

Johnson & Johnson has reported new model based analyses from the Phase III MajesTEC 3 study evaluating TECVAYLI, also known as teclistamab cqyv, in combination with DARZALEX FASPRO, or daratumumab and hyaluronidase fihj, in patients with relapsed or refractory multiple myeloma.

The analyses assessed patients who had received between one and three previous lines of treatment and explored the potential longer term survival impact of the combination.

Using a relative survival mixture cure model together with observed progression free survival and overall survival data from MajesTEC 3, researchers estimated that around 87% of patients treated with TECVAYLI plus DARZALEX FASPRO could eventually have a mortality risk and projected life expectancy similar to that of an age matched general population.

The modelling also suggested that median overall survival with the combination could be almost four times longer than with the standard of care comparator used in the trial.

The comparator consisted of dexamethasone combined with either pomalidomide or bortezomib.

Johnson & Johnson said the findings indicate that treatment with TECVAYLI plus DARZALEX FASPRO as early as second line therapy could substantially change longer term survival expectations for some patients with multiple myeloma.

MajesTEC 3 has already shown a statistically significant overall survival benefit for the combination compared with standard of care.

An estimated 83% of patients receiving TECVAYLI plus DARZALEX FASPRO were alive at three years.

A separate post hoc analysis examined the factors contributing to the survival improvement.

The analysis found that TECVAYLI plus DARZALEX FASPRO reduced the cumulative risk of multiple myeloma progression by 90% compared with standard treatment.

There was no statistically significant difference between the treatment groups in non relapse mortality over time.

Johnson & Johnson said the findings suggest the overall survival benefit was primarily driven by stronger control of multiple myeloma rather than differences in deaths unrelated to relapse.

The new analyses will be presented in two oral sessions at the International Myeloma Society Annual Meeting.

Johnson & Johnson said the results support its wider strategy of developing multiple myeloma therapies capable of delivering deeper and more durable disease control earlier in the treatment pathway.

The company is continuing to evaluate TECVAYLI based combinations across different stages of multiple myeloma as part of its broader portfolio in the disease.

---

---

Related Topics and Keywords

cancer research, clinical trials, DARZALEX FASPRO®, haemotology, johnson and johnosn, multiple myeloma, Oncology, pharma news, teclistamab, tecvayli